Placeholder Banner

BIO Expands Cooperation with China-Based Pharma Group

June 22, 2017

San Diego, CA (June 22, 2017) – Today Biotechnology Innovation Organization announced the signing of a Memorandum of Understanding for Cooperation (MOU) with the Pharmaceutical Association Committee (RDPAC). RDPAC is a non-profit organization located within the China Association of Enterprises with Foreign Investment (CAEFI) and has a membership of 38 multi-national companies with pharmaceutical R&D capabilities in China.

The MOU will further enable the two associations to collaborate closely on activities and issues of common interest, as well as to further develop partnerships in China.

Joe Damond, the Executive Vice President, International Affairs at BIO, said: “This agreement continues the longstanding relationship between BIO and RDPAC and deepens our cooperative efforts to advance advocacy and outreach for the biotechnology industry in China. Together we will continue to highlight the value of this industry in benefiting society and addressing global health challenges.”

Future cooperative efforts will focus on several areas, including expert-level exchange, research, and workshops. BIO and RDPAC are committed to creating an environment that promotes innovation and greater integration of China into the global biopharmaceutical ecosystem.

 

###

Discover More
Public opinion polls show there is significant mistrust among the American public in the safety and efficacy of vaccines. So today, the Biotechnology…
Washington, DC (December 2, 2020) - Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement regarding Nasdaq's filing with the Securities and Exchange Commission…
Washington, DC (November 20, 2020) – Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement after the Trump administration moved forward with its threat to impose…